Design Therapeutics (DSGN) News Today $5.53 -0.11 (-1.95%) Closing price 04:00 PM EasternExtended Trading$5.54 +0.00 (+0.09%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DSGN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Design Therapeutics to Participate in the 2025 Cantor Global Healthcare ConferenceAugust 27 at 8:00 AM | globenewswire.comDesign Therapeutics (NASDAQ:DSGN) Trading Up 1.3% - Time to Buy?August 20, 2025 | marketbeat.comLeerink Partnrs Has Negative Forecast for DSGN Q3 EarningsAugust 17, 2025 | marketbeat.comDesign Therapeutics (NASDAQ:DSGN) Announces Earnings Results, Misses Estimates By $0.02 EPSAugust 11, 2025 | marketbeat.comDesign Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comDesign Therapeutics (DSGN) Projected to Post Earnings on MondayJuly 28, 2025 | marketbeat.comDesign Therapeutics (NASDAQ:DSGN) Stock Price Down 3.1% - Should You Sell?July 18, 2025 | marketbeat.comDesign Therapeutics Inc (DSGN) - Investing.comJuly 10, 2025 | investing.comTwo Sigma Investments LP Trims Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)June 5, 2025 | marketbeat.comDesign Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2June 4, 2025 | globenewswire.comTwo Sigma Advisers LP Decreases Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)June 1, 2025 | marketbeat.comDesign Therapeutics to Participate in 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comPoint72 Asset Management L.P. Buys 256,010 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)May 21, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Cuts Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)May 21, 2025 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Stock Holdings Increased by Dimensional Fund Advisors LPMay 18, 2025 | marketbeat.comMPM Bioimpact LLC Purchases New Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)May 16, 2025 | marketbeat.comBridgeway Capital Management LLC Has $792,000 Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)May 14, 2025 | marketbeat.comDesign Therapeutics to Participate in 2025 RBC Capital Markets Healthcare ConferenceMay 13, 2025 | globenewswire.comQ2 EPS Forecast for Design Therapeutics Reduced by AnalystMay 13, 2025 | marketbeat.com776,082 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Bought by Driehaus Capital Management LLCMay 12, 2025 | marketbeat.comDesign Therapeutics (DSGN) to Release Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comDesign Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial ResultsMay 7, 2025 | globenewswire.comDesign Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025May 3, 2025 | nasdaq.comDesign Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal DystrophyMay 1, 2025 | globenewswire.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Shares Purchased by Walleye Capital LLCApril 24, 2025 | marketbeat.comDesign Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025April 22, 2025 | nasdaq.comDesign Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025April 21, 2025 | globenewswire.comDesign Therapeutics appoints Chris Storgard as CMOApril 18, 2025 | markets.businessinsider.comDesign Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical OfficerApril 17, 2025 | globenewswire.comBright Peak Therapeutics Appoints John Schmid to its Board of DirectorsApril 17, 2025 | markets.businessinsider.comWall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High?March 12, 2025 | msn.comDesign Therapeutics price target raised to $5 from $4 at RBC CapitalMarch 11, 2025 | markets.businessinsider.comDesign Therapeutics (DSGN) Gets a Hold from RBC CapitalMarch 11, 2025 | markets.businessinsider.comDesign Therapeutics (DSGN) to Release Earnings on TuesdayMarch 11, 2025 | marketbeat.comDesign Therapeutics sees cash runway into 2029March 10, 2025 | markets.businessinsider.comDesign Therapeutics provides corporate highlights, anticipated milestonesMarch 10, 2025 | markets.businessinsider.comDesign Therapeutics (NASDAQ:DSGN) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPSMarch 10, 2025 | marketbeat.comDesign Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 10, 2025 | globenewswire.comDesign Therapeutics to Participate in Leerink’s Global Healthcare ConferenceMarch 3, 2025 | markets.businessinsider.comDesign Therapeutics to Participate in Leerink's Global Healthcare ConferenceMarch 3, 2025 | globenewswire.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Short Interest UpdateFebruary 4, 2025 | marketbeat.comDesign Therapeutics: Not A Complete Washout Despite SetbackJanuary 31, 2025 | seekingalpha.comAssenagon Asset Management S.A. Trims Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN)January 26, 2025 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Up 8.1% in DecemberJanuary 19, 2025 | marketbeat.comDesign Therapeutics Updates Corporate Presentation for InvestorsJanuary 13, 2025 | tipranks.comDeepa Prasad Sells 3,806 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) StockDecember 20, 2024 | insidertrades.comDesign Therapeutics (NASDAQ:DSGN) Stock Quotes, Forecast and News SummaryDecember 20, 2024 | benzinga.comInsider Selling: Design Therapeutics, Inc. (NASDAQ:DSGN) Director Sells 3,806 Shares of StockDecember 19, 2024 | marketbeat.comFmr LLC Has $4.46 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)December 14, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Buys 697,368 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)December 10, 2024 | marketbeat.com Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DSGN Media Mentions By Week DSGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DSGN News Sentiment▼0.931.03▲Average Medical News Sentiment DSGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DSGN Articles This Week▼21▲DSGN Articles Average Week Get the Latest News and Ratings for DSGN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Design Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies COLL News PHVS News CALT News TLRY News ELVN News GPCR News NTLA News LENZ News RCUS News STOK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DSGN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access